Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Sellas Life Sciences Group Inc SLS

Healthcare Biotechnology
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of novel therapeutics for a range of cancer indications. The Company's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:SLS)

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire March 28, 2024

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study

GlobeNewswire March 26, 2024

SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

GlobeNewswire March 19, 2024

SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET

GlobeNewswire March 19, 2024

SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

GlobeNewswire March 15, 2024

SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships

GlobeNewswire March 8, 2024

SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference

GlobeNewswire March 1, 2024

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time

GlobeNewswire February 29, 2024

SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget

GlobeNewswire February 6, 2024
View More News ››

Opinion & Analysis (NDAQ:SLS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:SLS)

SLS....NR bump

FDA mentioned....$1.04
Iseneschal - November 13, 2023

RE:225 $

lol what nonsense pump. did you write your nonsense and then take off? haha
unclepieman - December 30, 2020

still holding this stock

from last year,it did a reverse split,but it's trying to make a comeback,so glta shareholders.
coolfooldumbguy - February 26, 2020

Breaking News

http://jhoponline.com/ton-web-exclusives/17423-sellas-announces-promising-data-on-neuvax-in-combination-with-herceptin-in-her2-1-2-breast...
kwhistler64 - December 2, 2019

Easy double

Best double opportunity for the week
parmagiana - November 11, 2019

225 $

https://www.zacks.com/stock/research/SLS/brokerage-recommendations
kwhistler64 - November 11, 2019
View more Bullboard ››

Lithium Ionic Corp

Lithium Ionic Corp

Lithium Ionic Corp. is a Canadian mining company. The Company is engaged exploring and developing its lithium properties in ...
View More »